Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico

Elham Omer Mahgoub1, Syed Asif Husain2

  • 1College of Arts and Sciences, Qatar University; ilhamomer@yahoo.com.

Insights

Novel cyclophilin A inhibitors and Ganoderiol F derivatives were designed and tested as potential cancer drug candidates. Molecular docking and simulations confirmed a stable interaction, identifying key amino acids for drug development against cancer cells.

Area of Science:

  • Medicinal Chemistry
  • Computational Biology
  • Oncology

Background:

  • The cyclin Ds-CDKs axis, involving Cyclophilin A (Cyp A) and Ganoderiol F, is crucial in cancer progression.
  • Ganoderiol F derivatives show promise as oncogenic targets for various cancer types.

Purpose of the Study:

  • To design and develop novel Cyp A inhibitors and Ganoderiol F derivatives for cancer therapy.
  • To optimize inhibitor effectiveness and receptor interaction through structure-guided design.
  • To computationally evaluate potential drug candidates for cancer treatment.

Main Methods:

  • Structure-guided design and molecular modeling using Chemsketch, AutoDock 4.2.6, PyMOL, Chimera, and Maestro.
  • Construction of 117 novel cyclophilin inhibitor ligand molecules.
  • Ligand-protein docking, docking confirmation, hydrogen bond detection, and molecular dynamics (MD) simulations using Gromacs with CHARMM 36 force field.

Main Results:

  • Identified active amino acids in the binding site, including Arginine 55, Asparagine, Glycine, Threonine, Lysine, Isoleucine, Histidine, Phenylalanine, and Cysteine.
  • Determined the optimal grid box coordinates (X: 38.86, Y: 10.987, Z: 40.734) for the 1nmk receptor-ligand complex.
  • MD simulations confirmed the stability of the selected ligand-receptor complex, indicating its potential as a cancer drug inhibitor.

Conclusions:

  • Novel Cyp A inhibitors and Ganoderiol F derivatives can be effectively designed using computational methods.
  • The identified ligand-receptor complex demonstrates stability and potential for development as an anti-cancer therapeutic agent.
  • This study provides a foundation for further investigation into these compounds for cancer treatment.

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...